Skip to Content


Prospective Grant of Exclusive Patent License: Treatment of Type I Diabetes and its Comorbidities

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


National Institutes of Health, HHS.




The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent License to Inversago Pharma, Inc., located in Montreal, Quebec, Canada, to practice the inventions embodied in the patent applications Start Printed Page 38708listed in the Supplementary Information section of this notice.


Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development August 22, 2018 will be considered.


Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Michael Shmilovich, Esq., Senior Licensing and Patent Manager, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479, phone number 301-435-5019, or

End Preamble Start Supplemental Information


The following and all continuing U.S. and foreign patents/patent applications thereof are the intellectual properties to be licensed under the prospective agreement to Inversago Pharma, Inc.:

HHS Reference No.Patent No. or application No.Filing dateTitle
E-282-2012-0-US-0161/725,949November 13, 2012Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-PCT-02PCT/US2013/069686November 12, 2013Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-039,765,031November 12, 2013Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-CA-042889697April 27, 2015Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-EP-0513802153.0June 01, 2015Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-IN-063733/DELNP/2015May 1, 2015Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-JP-072015-542015May 11, 2015Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-CN-08201380069389.9July 3, 2015Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-0915/674,365August 10, 2017Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-1015/674,333August 10, 2017Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-US-0161/991,333May 9, 2014Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-US-0162/171,179June 4, 2015Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-PCT-02PCT/US2016/035291June 1, 2016Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-EP-0516728547.7June 1, 2016Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-US-0815/579,123December 1, 2017Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-PCT-02PCT/US2015/029946May 8, 2015Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-AU-032015255765November 7, 2016Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-CA-042948349May 8, 2015Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-EP-0615728668.3May 8, 2015Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-CN-05201580028788.XMay 8, 2015Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-IN-07201637038171November 8, 2016Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-JP-082017-511558May 8, 2015Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-US-0915/309,728November 8, 2016Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-HK-1017105705.6June 9, 2017Cannabinoid Receptor Mediating Compounds

The patent rights in these inventions have been assigned to the Government of the United States of America. The prospective exclusive patent license territory will be granted worldwide and in a field of use not broader than human therapeutics for type I diabetes and its comorbidities diabetic nephropathy, chronic kidney disease, diabetic retinopathy, and peripheral and autonomic neuropathy.

The invention covered by the patents and patent applications pertaining to HHS Ref. No. E-282-2012-0 pertain to cannabinoid receptor 1 (CN1 R) inverse agonists. CN1 R activation plays a key role in appetitive behavior and metabolism. Of importance as a therapeutic target here is that the receptor is expressed in both peripheral tissue as well as the central nervous system. The invention is a class of pyrazole compounds that act as CN1 receptor inverse agonists and have been shown effective at reducing obesity and its associated metabolic consequences while having no experimentally discernable neuropsychotropic side effects that are considered adverse such as the earlier antagonists rimonabant. These CN1 R receptor compounds were developed with the goals of limiting their brain penetrance without losing their metabolic efficacy due to CN1 inverse agonism, and having a primary metabolite directly targeting enzymes involved in inflammatory and fibrotic processes associated with metabolic disorders. The patent rights cover both compositions of matter and methods of use.

The inventions covered by HHS Ref. E-140-2014-0 also pertain to pyrazole CN1 R receptor inverse agonists. In addition, some of these compounds also have a direct inhibitory effect on inducible nitric oxide synthase (iNOS), whereas another group of the compounds directly activates AMP kinase. There is evidence that the metabolic effects of endocannabinoids are mediated by CN1 receptors in peripheral tissues. These dual-target compounds may be useful for treating metabolic disease and related conditions such as obesity and diabetes and their complications, including liver or kidney fibrosis, without the dangerous the side effects.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive patent license will be royalty bearing and may be granted unless within fifteen (15) days from the date of this published notice, the NHLBI receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

Complete applications for a license in the prospective field of use that are timely filed in response to this notice will be treated as objections to the grant of the contemplated exclusive patent license.

Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Start Signature

Dated: July 25, 2018.

Michael A. Shmilovich,

Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development.

End Signature End Supplemental Information

[FR Doc. 2018-16836 Filed 8-6-18; 8:45 am]